Vita Life Sciences Limited · ASX:VLS

Vita Life Sciences — FY2019 Earnings Presentation

16 slides from Vita Life Sciences's earnings presentation, Feb 20, 2020

  1. Slide 1: Results Presentation Full Year Ended 31 Dec 2019

    RESULTS PRESENTATION FULL YEAR ENDED 31 DEC 2019 20 Feb 2020

  2. Slide 2: Vita Life Sciences Overview

    VITA LIFE SCIENCES OVERVIEW • Australian & Asia Pacific based pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements • 3 major consumer retail brands • 750-800 registered SKUs of vitamins and supplements sold

  3. Slide 3: FY 2019 - Group Summary

    FY 2019 - GROUP SUMMARY #039;000 2019 2018 Change Revenue 42,452 41,151 1,301 3.2% ↑ Reported EBIT 4,443 4,351* 92 2.1% ↑ Net profit after tax 3,094 2,433 661 27.2% ↑ Dividends declared (cents) 3.75 3.75 - 0% - *After revaluation charge of $1.8m in 2018 During the year 2019, the Company returned $2.2 m

  4. Slide 4: Segment Results Australia

    SEGMENT RESULTS Sales ($’m) AUSTRALIA 16.0 H2 H2 12.0 Sales: $16.6m (2018: $16.4m) 8.0  Revenue base business delivered marginal growth H1 H1 4.0  Channel expansion into selected pharmacies generated positive gains with 300 new - customers, partially offset by lower sales from 2019 2018 the health

  5. Slide 5: Segment Results Malaysia

    Sales ($’m) SEGMENT RESULTS 16 MALAYSIA 12 8 H2 H2 Sales $15.5m (2018: $14.9m) 4 H1  Revenue from operations increased by 4% underpinned by strong H1 performance of the Herbs of Gold brand 0  Domestic market remained competitive for the VitaHealth brand. 2019 2018 A combination of new product laun

  6. Slide 6: Segment Results Singapore

    Sales ($’m) SEGMENT RESULTS SINGAPORE 6 H2 H2 4 Sales $5.9m (2018: $6.9m) 2 H1 H1  Revenue was lower due to the challenging trading conditions  Shifting towards e-commerce requires increase trade 0 investment and discounting 2019 2018 EBIT ($’m) EBIT $0.5m (2018: $1.6m) 2  EBIT decreased mainly d

  7. Slide 7: Segment Results Others

    SEGMENT RESULTS OTHERS Sales ($’m) Sales $4.3m (2018: $2.9m) 4  Revenue grew by 49% principally on the back of H2 Vietnam sales and higher exports H2 2  Thailand sales were consistent with PCP H1 H1 0 EBIT Loss $0.2m (2018: $0.3m) 2019 2018  EBIT loss reduced mainly due to the higher profits in V

  8. Slide 8: Final Dividend & Cashflow

    FINAL DIVIDEND & CASHFLOW • Final dividend declared of 2.25 cents per share for FY 2019 (2018: 2.25 cents) • Final dividend fully franked • Dividend reinvestment plan is currently suspended Gross operating cashflow to EBITDA 100% 75% 50% 25% 0% 2019 2018 EBITDA above excludes gain on disposal of inv

  9. Slide 9: Strategic Priorities and Outlook

    Strategic Priorities and Outlook • To expand the sale of Herbs of Gold products into the Australian pharmacy channel • To increase the sale of products to China and Vietnam via new distributor arrangements for the VitaHealth and Herbs of Gold brands • Continued branding and promotional investment of

  10. Slide 10: Appendix

    APPENDIX

  11. Slide 11: Appendix 1 - Geographical Revenue

    APPENDIX 1-GEOGRAPHICAL REVENUE 2019 revenue by geography 2018 revenue by geography Other Asia Australia 7% 41% Other Australia Asia 40% 7% Singapore Singapore 17% 17% Asia Asia 59% 60% Malaysia Malaysia 36% 35% Total revenue: $42.4m Total revenue: $41.1m

  12. Slide 12: Appendix 2 - Profit & Loss

    APPENDIX 2 – PROFIT & LOSS Full year ended Dec 2019 2018 $’m $’m Revenue 42.4 41.1 EBITDA 5.0 4.8 EBIT 4.4 4.4 Profit before tax 4.4 4.3 Profit after tax 3.1 2.4 EPS (Basic – cents/ share) 5.73 4.44 Dividend (cents / share) 3.75 3.75

  13. Slide 13: Appendix 3 - Balance Sheet

    APPENDIX 3 – BALANCE SHEET Balance Sheet as at Dec 2019 Dec 2018 $’m $’m Current assets 25.8 24.8 Non-current assets 10.7 10.9 Total assets 36.5 35.7 Current liabilities 12.1 11.4 Non-current liabilities 1.9 1.9 Total Liabilities 14.0 13.3 Net Assets 22.5 22.4

  14. Slide 14: Appendix 4 - Cash Flow

    APPENDIX 4 – CASH FLOW Cash Flow for the year ended Dec 2019 2018 $’m $’m Receipts from customers 45.1 44.6 Payments to suppliers and employees 41.2 38.1 Gross operating cash flow 3.9 6.5 Adjusted EBITDA (ex LTIP exp and gain on disposal investments/ 4.8 6.6 revaluation adjustments in 2018) Gross op

  15. Slide 15: Contact

    CONTACT Telephone: +61 2 9545 2633 Website: vitalifesciences.com Email: enquiries@vitalifesciences.com Head Office: 1/102 Bath Road, Kirrawee, NSW 2232 Contact: Andrew O’Keefe (Managing Director)/ Chin L Khoo (Chief Financial Officer)

  16. Slide 16: Disclaimer

    DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a

Vita Life Sciences — FY2019 Earnings Presentation on 6ix